Penetration of echinocandins into wound secretion of critically ill patients.

Echinocandin antifungals Invasive candidiasis Target-site pharmacokinetics Vacuum assisted closure therapy Wound infection

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 22 12 2020
accepted: 08 03 2021
pubmed: 21 4 2021
medline: 26 11 2021
entrez: 20 4 2021
Statut: ppublish

Résumé

Wound infections caused by Candida are life-threatening and difficult to treat. Echinocandins are highly effective against Candida species and recommended for treatment of invasive candidiasis. As penetration of echinocandins into wounds is largely unknown, we measured the concentrations of the echinocandins anidulafungin (AFG), micafungin (MFG), and caspofungin (CAS) in wound secretion (WS) and in plasma of critically ill patients. We included critically ill adults with an indwelling wound drainage or undergoing vacuum-assisted closure therapy, who were treated with an echinocandin for suspected or proven invasive fungal infection. Concentrations were measured by liquid chromatography with UV (AFG and MFG) or tandem mass spectrometry detection (CAS). Twenty-one patients were enrolled. From eight patients, serial WS samples and simultaneous plasma samples were obtained within a dosage interval. AFG concentrations in WS amounted to < 0.025-2.25 mg/L, MFG concentrations were 0.025-2.53 mg/L, and CAS achieved concentrations of 0.18-4.04 mg/L. Concentrations in WS were significantly lower than the simultaneous plasma concentrations and below the MIC values of some relevant pathogens. Echinocandin penetration into WS displays a high inter-individual variability. In WS of some of the patients, concentrations may be sub-therapeutic. However, the relevance of sub-therapeutic concentrations is unknown as no correlation has been established between concentration data and clinical outcome. Nevertheless, in the absence of clinical outcome studies, our data do not support the use of echinocandins at standard doses for the treatment of fungal wound infections, but underline the pivotal role of surgical debridement.

Identifiants

pubmed: 33877638
doi: 10.1007/s15010-021-01604-x
pii: 10.1007/s15010-021-01604-x
pmc: PMC8316195
doi:

Substances chimiques

Antifungal Agents 0
Echinocandins 0
Lipopeptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

747-755

Subventions

Organisme : Austrian Science Fund FWF
ID : KLI 565
Pays : Austria
Organisme : Austrian Science Fund
ID : KLI 565-B3

Informations de copyright

© 2021. The Author(s).

Références

Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506
pubmed: 20385855
Infection. 2017 Dec;45(6):737-779
pubmed: 28702763
Injury. 2019 Dec;50(12):2234-2239
pubmed: 31630781
Clin Infect Dis. 2009 Jun 15;48(12):1676-84
pubmed: 19419331
Turk Arch Otorhinolaryngol. 2020 Mar;58(1):56-60
pubmed: 32313897
Infect Dis (Lond). 2019 Jan;51(1):1-11
pubmed: 30264627
Mil Med. 2018 Sep 1;183(suppl_2):142-146
pubmed: 30189071
Antimicrob Agents Chemother. 2013 Apr;57(4):1672-6
pubmed: 23335738
Int J Antimicrob Agents. 2017 Sep;50(3):352-358
pubmed: 28689871
BMC Infect Dis. 2015 Apr 15;15:184
pubmed: 25886578
Antimicrob Agents Chemother. 2015 Aug;59(8):4403-9
pubmed: 25963988
Clin Infect Dis. 2002 Dec 1;35(11):1316-20
pubmed: 12439793
J Infect Chemother. 2011 Oct;17(5):731-4
pubmed: 21537970
Chest. 2012 May;141(5):1327-1336
pubmed: 22553267
J Antimicrob Chemother. 2007 Jul;60(1):100-6
pubmed: 17525052
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Feb 15;1139:121937
pubmed: 31958565
Clin Microbiol Rev. 2014 Jan;27(1):68-88
pubmed: 24396137
Intensive Care Med. 2015 Feb;41(2):371-2
pubmed: 25465909
Antimicrob Agents Chemother. 2011 May;55(5):2113-21
pubmed: 21300835
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):93-7
pubmed: 23771854
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Antimicrob Agents Chemother. 2012 Feb;56(2):1113-5
pubmed: 22083486
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5914-21
pubmed: 27458229
J Antimicrob Chemother. 2020 Oct 1;75(10):2969-2976
pubmed: 32696036
Antimicrob Agents Chemother. 2010 Feb;54(2):943-4
pubmed: 19933794
Surg Infect (Larchmt). 2021 Feb;22(1):83-87
pubmed: 33035112

Auteurs

Tiziana Gasperetti (T)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

René Welte (R)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Herbert Oberacher (H)

Institute of Legal Medicine and Core Facility Metabolomics, Medical University of Innsbruck, Innsbruck, Austria.

Jana Marx (J)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Ingo Lorenz (I)

General and Surgical ICU, University Hospital for Anaesthesia and Intensive Care, Medical University of Innsbruck, Innsbruck, Austria.

Peter Schellongowski (P)

Intensive Care Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Thomas Staudinger (T)

Intensive Care Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Karin Burgmann (K)

Intensive Care Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Philipp Eller (P)

Intensive Care Unit, Department of Internal Medicine, University Hospital of Graz, Graz, Austria.

Tobias Santner (T)

Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck General Hospital, Innsbruck, Austria.

Andrea Griesmacher (A)

Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck General Hospital, Innsbruck, Austria.

Hartwig Pfisterer (H)

Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck General Hospital, Innsbruck, Austria.

Stephan Eschertzhuber (S)

Transplant ICU, University Hospital for Anaesthesia and Intensive Care, Innsbruck General Hospital and Innsbruck Medical University Innsbruck, Innsbruck, Austria.
Department of Anaesthesia and Critical Care, District Hospital of Hall in Tyrol, Hall in Tyrol, Austria.

Maria Aigner (M)

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
INNPATH GmbH, Tirol Kliniken, Innsbruck, Austria.

Michael Joannidis (M)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.

Romuald Bellmann (R)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. romuald.bellmann@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH